Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.00% 31.30 2,500 08:00:00
Bid Price Offer Price High Price Low Price Open Price
31.00 31.60 31.30 31.30 31.30
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.39 -0.79 -2.00 15.0
Last Trade Time Trade Type Trade Size Trade Price Currency
15:11:13 O 2,500 31.00 GBX

Ixico (IXI) Latest News

More Ixico News
Ixico Takeover Rumours

Ixico (IXI) Share Charts

1 Year Ixico Chart

1 Year Ixico Chart

1 Month Ixico Chart

1 Month Ixico Chart

Intraday Ixico Chart

Intraday Ixico Chart

Ixico (IXI) Discussions and Chat

Ixico Forums and Chat

Date Time Title Posts
01/12/201616:17Ixico PLC79

Add a New Thread

Ixico (IXI) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
2019-06-26 14:11:1331.002,500775.00O
View all Ixico trades in real-time

Ixico (IXI) Top Chat Posts

Ixico Daily Update: Ixico Plc is listed in the Pharmaceuticals & Biotechnology sector of the London Stock Exchange with ticker IXI. The last closing price for Ixico was 31.30p.
Ixico Plc has a 4 week average price of 25.50p and a 12 week average price of 25.50p.
The 1 year high share price is 43.50p while the 1 year low share price is currently 19p.
There are currently 46,777,000 shares in issue and the average daily traded volume is 31,222 shares. The market capitalisation of Ixico Plc is £14,641,201.
jpuff: Great news, but never seems to lift the share price alas.
jondev: Has the share price gone down because they spent 2.7 million buying some random company with no consultation from shareholders???
geoff80: LSE:IXI OKSearch Ixico Share News (IXI) 5 Follow IXI Share Name Share Symbol Market Type Share ISIN Share Description Ixico LSE:IXI London Ordinary Share GB00BCLY7L40 ORD 1P Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade +0.50p +2.04% 25.00p 24.00p 26.00p 25.00p 24.50p 24.50p 7,318 10:06:15 Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m) Pharmaceuticals & Biotechnology 3.1 -1.4 -7.9 - 6.62 Print Alert IXICO plc Participation in major EU partnership (ROADMAP) 16/11/2016 7:00am UK Regulatory (RNS & others) IXICO plc 16 November 2016 16(th) November 2016 IXICO plc ("IXICO" or the "Company") IXICO to receive EUR100k funding to provide digital technologies for collection and analysis of data in a "real world" setting Further expansion of work on wearable bio-sensors as part of a major EU public-private partnership (ROADMAP) IXICO, the brain health company, today announces its participation in a new collaborative pan-European research effort under the Innovative Medicines Initiative's (IMI) umbrella focused on addressing the challenges of successfully delivering therapies to people with Alzheimer's disease (AD). In this collaboration with leading pharmaceutical companies and academics, IXICO is receiving EUR100k of funding to undertake data aggregation and analysis using its digital technology platforms. The platforms will be used to devise clinically meaningful measurements from biosensors worn by patients, and to develop enhanced models of disease progression to help select the most appropriate treatment for an individual patient. Within ROADMAP, IXICO will demonstrate how both approaches can be deployed in real-world settings, leveraging IXICO's existing activities in the Cygnus real world evidence (RWE) study (hxxp:// Derek Hill, CEO of IXICO, said: "IXICO is delighted to be joining the ROADMAP consortium. It provides an excellent opportunity for us to advance our capabilities in wearable biosensors and digital disease models, working collaboratively with leading pharmaceutical companies and academics. These are key technologies that are likely to accelerate the approval of and access to beneficial treatments for AD, and we believe they will provide commercial growth opportunities for IXICO." This project will enhance capabilities currently integrated into IXICO's TrialTracker(TM) and Assessa(R) digital health platforms, which are used by pharmaceutical companies both to support development of new treatments and used alongside marketed drugs. This innovative collaboration brings together 22 leading academic, healthcare and pharmaceutical partners, including Novartis Pharma AG, Eli Lilly and Company Ltd, Biogen, F. Hoffman-La Roche Ltd, Janssen Pharmaceutica NV, GE Healthcare Ltd and AC Immune SA. ROADMAP is also looking to identify which combinations of clinical tests and biomarkers support accurate diagnosis and prognosis of disease in asymptomatic patient populations in Alzheimer's disease. For further information please contact: IXICO plc Derek Hill, Chief Executive Officer Tel: +44 20 Susan Lowther, Chief Financial Officer 3763 7499 Shore Capital (Nomad and Broker) Tel: +44 20 Bidhi Bhoma / Edward Mansfield 7408 4090 FTI Consulting Limited (Investor Tel: +44 20 Relations) 3727 1000 Simon Conway/Mo Noonan/Matthew Moss About IXICO IXICO's innovative and proprietary digital healthcare technologies help those involved in researching and treating serious diseases to capture and analyse clinical data to make rapid, informed decisions. In clinical research this includes the phenotyping of patients, quantification of disease pathology and measurement of patient outcomes. In clinical practice the mobile health and digital decision support technologies aid diagnosis, patient engagement and monitoring. IXICO is also collaborating with partners to develop companion digital health products targeted at improving patient outcomes. The Company's brain health focus includes Alzheimer's disease, Huntington's disease, multiple sclerosis, Parkinson's disease, behavioural health, child and adolescent mental health. More information is available on About ROADMAP ROADMAP aims to provide the foundation for a much-needed integrated data environment and framework for Real World Evidence (RWE) in AD including: -- The development of consensual key outcome measures across stakeholder groups; -- Enabling data integration tools for dataset characterisation and outcome classification, data standards, data sourcing, software application repository; -- Guidelines on the handling and interpretation of RWE data. In addition, the following priorities have been identified: -- Outcome measurement; -- Identifying the best natural history model; -- Identifying the best pharmacoeconomic modelling strategy; -- Using short-term data to model long-term effects; -- Using short-term data to model long-term economic impact; -- Association between cognition, QoL (quality of life) and function over the AD spectrum; -- Identifying combination markers for diagnosis in asymptomatic patient population; -- Identifying combination markers for prognosis. ROADMAP is mainly sponsored by the European Union's Horizon 2020 research and innovation programme and the European pharmaceutical industry (via EFPIA) under the auspices of the Innovative Medicines Initiative 2 Joint Undertaking. The ROADMAP programme has budget of EUR7.77M distributed across a total of 22 partners from the private and academic sectors: * The University of Oxford * London School of Economics and Political Science * National Institute for Health and Care Excellence * Agentschap College ter Beoordeling van Geneesmiddelen * Erasmus Universitair Medisch Centrum Rotterdam * IXICO Technologies Ltd * Universiteit Maastricht * Rijksuniversiteit Groningen * Synapse Research Management Partners S.L. * Novartis Pharma AG (Project Leader) * Fundació Institut Universitari per la Recerca a * Eli Lilly and Company Ltd l'Atenció Primària de Salut Jordi Gol i Gurina * Biogen * Københavns Universitet * F. Hoffman-La Roche Ltd * Alzheimer Europe * Janssen Pharmaceutica NV * The University of Edinburgh * GE Healthcare Ltd * Goeteborgs Universitet * AC Immune SA * Aarhus Universitet About the Innovative Medicines Initiative The Innovative Medicines Initiative (IMI) is Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. IMI supports collaborative research projects and builds networks of industrial and academic experts in order to boost pharmaceutical innovation in Europe. IMI is a joint undertaking between the European Union and the European Federation of Pharmaceutical Industries and Associations, EFPIA. More information can be found at Acknowledgement The project leading to this application has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 116020. This
loobrush: Well not many seem interested in this share at the moment but as a healthcare share and in dementia they should be. Clearly undervalued, I expect that an analyst will pick this up soon, maybe when results out. Directors recently awarded options. The award of options under the Scheme are over the ordinary shares in the Company and are exercisable at an exercise price of 49.0p subject to various conditions. For each Executive Director, half of the options will not vest earlier than one year from the date of grant and will be subject to absolute share price performance. The options will vest in equal tranches on the first, second the third anniversary of grant with an annual hurdle of 10% share price appreciation being required in any 12 month period. The other half of the options are subject to a number of enhanced performance criteria including a more than doubling of the share price in a twelve month period or other corporate and strategic goals being met. So Directors have options which are only exercisable if share price goes up and minimum level to get some is 49p+10% = 54p -that's 35% above today's price. Also some of the options subject to DOUBLING SHARE PRICE That's a big incentive to get the company really moving.
loobrush: lse board Ixico has dropped to a low for the year at 35p and in my view is due for a big bounce. The company is one of two on the market involved in Dementia diagnosis and has recently launched a dimentia diagnostic kit which it is promoting. With the immense focus on this disease by the government this could turn into really big business Directors were recently granted options at 49p with the ability to take these up subject to increasing the share price from 49p. The company has been doing very well lately too. An update is due from the company in December Cash in the bank of over £3 million and company valued at only £5.25 million inc cash this has got to be a steal. Was as high as 120p has dropped a lot.
loobrush: see RNS Prof Hill MD of IXico speaking in China again with UK Minister of oF Health. I don't think he is there just to talk, is another deal in the offing ? await contract news and a share price jump
loobrush: I think you may be wrong in your assumption that its not worth chasing ,as you have pointed out with only a few shares being traded this exagerates the price movement, both up and down. However most investors have not cottoned on to what this company actually does and what the potential is. A visit to the IXICO website explains this in some detail and is very worthwhile, however this does not provide any financial projections of the three areas of their business. I am advised that this will be forthcoming in the new year. However, waiting until this is available or the company is anylised in the press or elsewhere may be unwise as the share price will take off again on any positive comment and you may miss the boat.
loobrush: latest grant award is brilliant news. Cash is rolling in with half the companies value in by cash in hand valuing the whole business at only £9 million To find out more what the company is about look at this info on They are finalising the design of the diagnostic kit to enable it to be used worldwide in conjunction with AstraZeneca and Imperial College plus other unnamed large company. See latest RNS They have global ambitions. Share price wont stay at these levels for long.
loobrush: from coldascheese on iii board "Researching more into and dementia and the other brain problems that there are I have only just understood how really big the problem is and what this will mean for IXICO. According to article in the Daily mail today(10 December) page 51, 25 billion has been spent on research into cures and treatments of DEMENTIA and ALZHEIMER'S and the amount is going to increase dramatically. Tomorrow sees the start of the G8 summit in London on this problem where all the experts from the worlds leading economies will meet to coordinate an action plan for tackling this. Professor Hill the chief exec of IXICO who recently signed the deal with the Chinese Academy of Medical Science will be in attendance. Tonight on NEWSNIGHT this summit meeting and the action required from it was discussed in more detail with the minister responsible advising that a great deal t more money was going to be spent on research into this problem. With Professor Hill and his team at IXICO being the only quoted company in this field and WORLD LEADERS at what the do in research IXICO will receive much greater publicity than of late and show what a truly great opportunity exists with this company and share price. They are already earning money and have over 8 million in the bank so are not like your usual cash hungry research/medical companies on multiple pe ratios valued at ten times the amount. I would also remind all about the company from their recent Aim Listing IXICO brings innovative technologies to those researching, diagnosing and treating serious diseases, especially dementia. Its technologies enable timely decision-making aimed at improving patient outcomes. IXICO was founded with a mission to translate image acquisition, management and analysis technology and know-how, which the founders had developed together, into commercial products. These target the expanding area of imaging to inform decision-making during drug development, especially for treatments for Alzheimer's Disease and other brain disorders. This has resulted in commercially successful products being launched in the clinical trials and experimental medicine markets and such products are now being readied for launch into the wider clinical diagnostic market to support the diagnosis of dementia Products ready for launch it says. Small holding PI's who have not understood the potential here have been selling today I would advise them to do bit more research as the potential of the company and what could come from this summit to the benefit of IXICO will be truly dramatic. The Chinese have recognized it-this share will be many multiples of todays price in a years time. " THIS HAS GOT TO BE AN OUSTANDING BUY AND I AM ADDING TO MY HOLDING
Ixico share price data is direct from the London Stock Exchange
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190627 00:09:37